ISTA Pharmaceuticals, Inc. - SWOT, Strategy and Corporate Finance Report

ISTA Pharmaceuticals, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.

Features:

- Detailed information on ISTA Pharmaceuticals, Inc. required for business and competitor intelligence needs
- A study of the major internal and external factors affecting ISTA Pharmaceuticals, Inc. in the form of a SWOT analysis
- An in-depth view of the business model of ISTA Pharmaceuticals, Inc. including a breakdown and examination of key business segments
- Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for ISTA Pharmaceuticals, Inc.
- Intelligence on ISTA Pharmaceuticals, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about ISTA Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

ISTA Pharmaceuticals, Inc. (ISTA or ‘the company’) is an ophthalmic pharmaceutical company engaged in the development and commercialization of products for the treatment of inflammation, ocular pain, glaucoma, allergy and dry eye. The company primarily operates in the US. It is headquartered in Madison, New Jersey and employed 330 people as of January 31, 2012. In June 2012, Bausch + Lomb, a global eye health company, completed the acquisition of ISTA for $500 million in an all cash transaction. ISTA recorded revenues of $160.3 million during the financial year ended December 2011 (FY2011), an increase of 2.4% over FY2010. The increase in revenues was due to higher revenues of Bepreve, Istalol and Vitrase. The operating profit of the company was $0.02 million in FY2011, as compared to an operating profit of $10.4 million. The net loss was $56.6 million in FY2011, as compared to a net loss of $5.3 million in FY2010.
Reasons to Purchase:

- Gain understanding of ISTA Pharmaceuticals, Inc. and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess ISTA Pharmaceuticals, Inc. as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers' businesses better
- Stay up to date on ISTA Pharmaceuticals, Inc.’s business structure, strategy and prospects

Company Snapshot
ISTA Pharmaceuticals, Inc.: Company Overview
ISTA Pharmaceuticals, Inc.: Overview and Key Facts
ISTA Pharmaceuticals, Inc.: Overview
ISTA Pharmaceuticals, Inc.: Key Facts
ISTA Pharmaceuticals, Inc.: Key Employees
ISTA Pharmaceuticals, Inc.: Key Employee Biographies
ISTA Pharmaceuticals, Inc.: Major Products and Services
ISTA Pharmaceuticals, Inc.: Company History
ISTA Pharmaceuticals, Inc.: Management Statement
ISTA Pharmaceuticals, Inc.: Locations and Subsidiaries
ISTA Pharmaceuticals, Inc.: Key Competitors
ISTA Pharmaceuticals, Inc.: Company Analysis
ISTA Pharmaceuticals, Inc.: Business Description
ISTA Pharmaceuticals, Inc.: SWOT Analysis
ISTA Pharmaceuticals, Inc.: SWOT Overview
ISTA Pharmaceuticals, Inc.: Strengths
ISTA Pharmaceuticals, Inc.: Weaknesses
ISTA Pharmaceuticals, Inc.: Opportunities
ISTA Pharmaceuticals, Inc.: Threats
ISTA Pharmaceuticals, Inc.: Corporate Financial Deals Activity
ISTA Pharmaceuticals, Inc.: Financial Deals Overview
ISTA Pharmaceuticals, Inc.: Targets and Partners
ISTA Pharmaceuticals, Inc.: Top Deals 2008 - 2012YTD*
ISTA Pharmaceuticals, Inc.: Advisors
ISTA Pharmaceuticals, Inc.: Top Legal Advisors
ISTA Pharmaceuticals, Inc.: Top Financial Advisors
ISTA Pharmaceuticals, Inc.: Private Equity and Ownership
ISTA Pharmaceuticals, Inc.: Recent Developments
ISTA Pharmaceuticals, Inc.: News and Events Summary
ISTA Pharmaceuticals, Inc.: Contracts
ISTA Pharmaceuticals, Inc.: Financial Performance
ISTA Pharmaceuticals, Inc.: Regulatory and Legal Events
ISTA Pharmaceuticals, Inc.: Research & Development
Appendix
Contact Us
Methodology
Definitions
About Datamonitor

List of Tables

Table 1: ISTA Pharmaceuticals, Inc.: Key Facts
Table 2: ISTA Pharmaceuticals, Inc.: Key Employees
Table 4: ISTA Pharmaceuticals, Inc.: Key Competitors
Table 5: ISTA Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (TTM*)
Table 6: ISTA Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (2008 - YTD*2012)
Table 7: ISTA Pharmaceuticals, Inc.: Targets and Partners
Table 8: ISTA Pharmaceuticals, Inc.: Top Deals 2008 - 2012YTD*
Table 9: ISTA Pharmaceuticals, Inc.: Legal Advisor Ranking by Value (US$m)
Table 10: ISTA Pharmaceuticals, Inc.: Financial Advisor Ranking by Value (US$m)
Table 11: ISTA Pharmaceuticals, Inc.: Private Equity and Ownership Volume and Value Trend (2008 - YTD*2012)
Table 12: ISTA Pharmaceuticals, Inc.: Private Equity and Ownership Volume by Deal Type (2008 - YTD*2012)
Table 13: ISTA Pharmaceuticals, Inc.: News and Events Summary
Table 14: ISTA Pharmaceuticals, Inc.: Contracts
Table 15: ISTA Pharmaceuticals, Inc.: Financial Performance
Table 16: ISTA Pharmaceuticals, Inc.: Regulatory and Legal Events
Table 17: ISTA Pharmaceuticals, Inc.: Research & Development

List of Figures

Figure 1: ISTA Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (TTM*)
Figure 2: ISTA Pharmaceuticals, Inc.: Deal Activity by Deal Type - Volume (2008 - YTD*2012)
Figure 3: ISTA Pharmaceuticals, Inc.: Private Equity and Ownership Volume and Value Trend (2008 - YTD*2012)
Figure 4: ISTA Pharmaceuticals, Inc.: Private Equity and Ownership Volume by Deal Type (2008 - YTD*2012)